- ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients
| Acronym |
ASPIRO |
| Intervention | AT132 |
| Principal investigators |
Andreea Seferian |
| Sponsor | Audentes |
| Study status | Active |
| Recruitment status | Completed |
| Population | Child |
| + infos on clinicaltrials.gov |
